MDT

88.67

-0.16%↓

VEEV

228.36

+0.56%↑

A

115.72

+0.77%↑

HQY

88.67

+0.86%↑

PDCO

31.27

+0.06%↑

MDT

88.67

-0.16%↓

VEEV

228.36

+0.56%↑

A

115.72

+0.77%↑

HQY

88.67

+0.86%↑

PDCO

31.27

+0.06%↑

MDT

88.67

-0.16%↓

VEEV

228.36

+0.56%↑

A

115.72

+0.77%↑

HQY

88.67

+0.86%↑

PDCO

31.27

+0.06%↑

MDT

88.67

-0.16%↓

VEEV

228.36

+0.56%↑

A

115.72

+0.77%↑

HQY

88.67

+0.86%↑

PDCO

31.27

+0.06%↑

MDT

88.67

-0.16%↓

VEEV

228.36

+0.56%↑

A

115.72

+0.77%↑

HQY

88.67

+0.86%↑

PDCO

31.27

+0.06%↑

Search

Avidity Biosciences Inc

Abierto

SectorSanidad

29.49 3.91

Resumen

Variación precio

24h

Actual

Mínimo

26.22

Máximo

29.73

Métricas clave

By Trading Economics

Ingresos

-22M

-102M

Ventas

637K

3M

BPA

-0.8

Margen de beneficios

-3,439.522

Empleados

391

EBITDA

-23M

-120M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+129.78% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

156M

3.8B

Apertura anterior

25.58

Cierre anterior

29.49

Noticias sobre sentimiento de mercado

By Acuity

40%

60%

138 / 386 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

Avidity Biosciences Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

1 abr 2025, 23:15 UTC

Principales Movimientos del Mercado

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

1 abr 2025, 23:46 UTC

Charlas de Mercado

Market Grapples With Valuing Goodman's Data Centers -- Market Talk

1 abr 2025, 23:44 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

1 abr 2025, 23:44 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

1 abr 2025, 23:44 UTC

Charlas de Mercado

Nikkei May Trade Rangebound Amid U.S. Tariff Uncertainty -- Market Talk

1 abr 2025, 23:43 UTC

Charlas de Mercado

Gold Steady, Underpinned by Signs of Chinese Buying Activity -- Market Talk

1 abr 2025, 23:11 UTC

Principales Noticias

Risk Off Trade Is Getting Crowded. It's More Worry Than Panic. -- Barrons.com

1 abr 2025, 23:02 UTC

Charlas de Mercado

New Zealand May Be Measuring Stick for Trade-War Fallout -- Market Talk

1 abr 2025, 22:31 UTC

Principales Noticias

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

1 abr 2025, 22:26 UTC

Charlas de Mercado

RBA's Focus on What It Doesn't Know Boosts May Cut Odds -- Market Talk

1 abr 2025, 21:47 UTC

Principales Noticias

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

1 abr 2025, 21:32 UTC

Principales Noticias

Hooters' Bankruptcy Is the Latest Sign of Trouble for Restaurants -- Barrons.com

1 abr 2025, 21:06 UTC

Charlas de Mercado

Mexican Remittances See Slow Start to the Year -- Market Talk

1 abr 2025, 21:00 UTC

Charlas de Mercado

ESG Roundup: Market Talk

1 abr 2025, 20:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Financial Services Roundup: Market Talk

1 abr 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

1 abr 2025, 20:47 UTC

Principales Noticias

Boeing Stock Drops. Why Lower 737 MAX Production Report Wasn't Quite Right. -- Barrons.com

1 abr 2025, 20:47 UTC

Principales Noticias

BYD Will Beat Tesla Two Ways This Quarter -- Barrons.com

1 abr 2025, 20:20 UTC

Principales Noticias

Trump's 'Liberation Day' Tariffs Loom; Treasury Yields Fall -- WSJ

1 abr 2025, 20:15 UTC

Adquisiciones, fusiones, absorciones

Eaton Completes Acquisition Of Fibrebond >ETN

1 abr 2025, 20:11 UTC

Charlas de Mercado

Altria Stock Seen Overvalued Amid Steep Volume Losses -- Market Talk

1 abr 2025, 20:07 UTC

Adquisiciones, fusiones, absorciones

Johnson & Johnson Intends to Complete Its Acquisition of Intra-Cellular Therapies on or Around April 2 >JNJ

1 abr 2025, 20:00 UTC

Principales Noticias

Americans Are Worried About Tariffs. Consumer Stocks Could Take a Hit. -- Barrons.com

1 abr 2025, 19:46 UTC

Principales Noticias

Visa, American Express Bidding to Win Apple Credit-Card Network, Sources Say -- WSJ

1 abr 2025, 19:43 UTC

Charlas de Mercado

Oil Rally Loses Momentum Ahead of U.S. Tariff Plans -- Market Talk

1 abr 2025, 19:17 UTC

Principales Noticias

Meta's Head of AI Research to Resign Amid Computing Push -- Update

1 abr 2025, 19:13 UTC

Charlas de Mercado

U.S. Natural Gas Futures Give Back Gains -- Market Talk

1 abr 2025, 19:03 UTC

Charlas de Mercado

Don't Rush Into Trade Talks With U.S., Canadian Experts Advise Lawmakers -- Market Talk

1 abr 2025, 19:00 UTC

Charlas de Mercado

Gold Slips Ahead of Tariff Day -- Market Talk

1 abr 2025, 18:54 UTC

Charlas de Mercado

Mexican Manufacturing PMIs Reflect Tariff Threats -- Market Talk

Comparación entre iguales

Cambio de precio

Avidity Biosciences Inc previsión

Precio Objetivo

By TipRanks

129.78% repunte

Estimación a 12 Meses

Media 67.83 USD  129.78%

Máximo 96 USD

Mínimo 48 USD

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Avidity Biosciences Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

12 ratings

12

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

N/A / 31.72Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

138 / 386 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Avidity Biosciences Inc

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.